Olaparib (Lynparza®) for breast cancer

Assessment Status Rapid Review Complete
Drug Olaparib
Brand Lynparza®
Indication For the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments.
Assessment Process
Rapid review commissioned 29/03/2019
Rapid review completed 10/04/2019
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.